Do We Need Heparin Coating for Extracorporeal Membrane Oxygenation? New Concepts and Controversial Positions About Coating Surfaces of Extracorporeal Circuits

Artificial Organs

Volumn 39, Issue 2, 2015, Pages 176-179

  Silvetti, Simona ^a   Koster, Andreas ^b   Pappalardo, Federico ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Blood coagulation Extracorporeal membrane; Oxygenation Heparin Circuit coating

Indexed keywords

BIOCOMPATIBILITY; BLOOD; OXYGENATION; POLYSACCHARIDES; RESPIRATORY THERAPY; TIMING CIRCUITS;

BLOOD COAGULATION; BLOOD COAGULATION-EXTRACORPOREAL MEMBRANE; BLOOD CONTACT; COAGULATION SYSTEM; COATING SURFACE; EXTRACORPOREAL CIRCUITS; EXTRACORPOREAL MEMBRANE OXYGENATION; EXTRACORPOREAL MEMBRANES; HEPARIN COATINGS; OXYGENATION-HEPARIN-CIRCUIT COATING;

COATINGS;

ARGATROBAN; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; HIRULOG; LEPIRUDIN; MACROGOL; PHOSPHORYLCHOLINE; POLYMER; SULFATE; ANTICOAGULANT AGENT;

ANGIOGRAPHY; ANTICOAGULATION; ARTICLE; BIOCOMPATIBILITY; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CARDIOVASCULAR EQUIPMENT; CELL ADHESION; ENDOTHELIUM CELL; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; FOREIGN BODY; HEART ATRIUM FIBRILLATION; HEART SURGERY; HEPARINIZATION; HUMAN; HYDROPHILICITY; INFLAMMATION; INTENSIVE CARE UNIT; LUNG TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; SURFACE PROPERTY; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VENTRICULAR ASSIST DEVICE; ADVERSE EFFECTS; CHEMICALLY INDUCED; DEVICES; DRUG EFFECTS;

ANTICOAGULANTS; BLOOD COAGULATION; EXTRACORPOREAL MEMBRANE OXYGENATION; HEPARIN; HUMANS; SURFACE PROPERTIES; THROMBOCYTOPENIA;

EID: 84922700340     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12335     Document Type: Article

References (25)

1. Khuri SF, Valeri CR, Loscalzo J, et al. Heparin causes platelet dysfunction and increases fibrinolysis before the institution of cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-1014.
2. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991;87:1787-1793.
3. FDA Information on Heparin. Updated June 6, 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm112597.htm. Accessed May 26, 2014.
4. Gott VL, Whiffen JD, Dutton RC. Heparin bonding on colloidal graphite surface. Science 1963;142:1297-1298.
5. Korn RL, Fisher CA, Livingston ER, et al. The effects of Carmeda bioactive surface on human blood components during simulated extracorporeal circulation. J Thorac Cardiovasc Surg 1996;111:1073-1084.
6. Fosse E, Moen O, Johnson E, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-477.
7. Weerwind PW, Maessen JG, van Tits LJ, et al. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 1995;110:1633-1641.
8. Ranucci M, Pazzaglia A, Isgrò G, et al. Closed, phosphorylcholine-coated circuit and reduction of systemic heparinization for cardiopulmonary bypass: the intraoperative ECMO concept. Int J Artif Organs 2002;25:875-881.
9. Wendel HP. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur J Cardiothorac Surg 1999;16:342-350.
10. Yu J, Lamba NM, Courtney JM, et al. Polymeric biomaterials: influence of phosphorylcholine polar groups on protein adsorption and complement activation. Int J Artif Organs 1994;17:499-504.
11. Von Segesser LK, Tönz M, Leskosek B, Turina M. Evaluation of phospholipidic surface coatings ex vivo. Int J Artif Organs 1994;17:294-299.
12. Pappalardo F, Della Valle P, Crescenzi G, et al. Phosphorylcholine coating may limit thrombin formation during high-risk cardiac surgery: a randomized controlled trial. Ann Thorac Surg 2006;81:886-891.
13. De Somer F, François K, van Oeveren W, et al. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur J Cardiothorac Surg 2000;18:602-606.
14. Thiara AS, Andersen VY, Videm V, et al. Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response. Perfusion 2010;25:9-16.
15. Ranucci M, Balduini A, Ditta A, Boncilli A, Brozzi SA. Systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome. Ann Thorac Surg 2009;87:1311-1319.
16. Ranucci M, Isgrò G, Soro G, Canziani A, Menicanti L, Frigiola A. Reduced systemic heparin dose with phosphorylcholine coated closed circuit in coronary operations. Int J Artif Organs 2004;27:311-319.
17. Ranucci M, Mazzucco A, Pessotto R, et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ann Thorac Surg 1999;67:994-1000.
18. Edmunds HL Jr. Surface-bound heparin-panacea or peril? Ann Thorac Surg 1994;58:285-286.
19. Cheung AT, Levin SK, Weiss SJ, Acker MA, Stenach N. Intracardiac thrombus: a risk of incomplete anticoagulation for cardiac operations. Ann Thorac Surg 1994;58:541-542.
20. Gorman RC, Ziats N, Rao AK, et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996;111:1-12.
21. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-2131.
22. Pappalardo F, Maj G, Scandroglio A, Sampietro F, Zangrillo A, Koster A. Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated. Perfusion 2009;24:135-137.
23. Koster A, Sänger S, Hansen R, et al. Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices. ASAIO J 2000;46:319-322.
24. Pieri M, Agracheva N, Bonaveglio E, et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth 2013;27:30-34.
25. Pappalardo F, Agracheva N, Covello RD, et al. Anticoagulation for critically ill cardiac surgery patients: is primary bivalirudin the next step? J Cardiothorac Vasc Anesth 2014 Jan 18;pii: S1053-0770(13)00528-4. doi: 10.1053/j.jvca.2013.10.004; [Epub ahead of print].